Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Darinaparson · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Darinaparson | DRUG | 420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months |
Inclusion Criteria 1. Subjects with a confirmed diagnosis of active multiple myeloma with measurable protein criteria present to evaluate response. Measurable disease is defined as having at least one of the following criteria within 28 days prior to registration: 1. Serum M-protein level \> 0....
Top 20 of 24 competitors